CASES Insights Into HER2 Breast Cancer Southeast

Perspectives from community oncologists from the southwest region of the US on current treatment practices regarding HER2+ metastatic breast cancer, and attitudes toward recently introduced and upcoming agents

Southeast May 16, 2020

Faculty Chair

Sara Hurvitz, MD

David Geffen School of Medicine at UCLA, CA, US

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

  • A roundtable discussion, moderated by an Axess Oncology Network physician, focusing on treatment of HER2+ breast cancer was held on May 16, 2020, in a virtual setting
  • Disease state and data presentations were developed in conjunction with Sara Hurvitz, MD, a medical expert from David Geffen School of Medicine at UCLA
  • Insights on the following breast cancer therapies were obtained
  • Trastuzumab (and biosimilars), lapatinib, pertuzumab, T-DM1, neratinib, tucatinib, trastuzumab deruxtecan, AIs, chemotherapies

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • A moderated virtual roundtable discussion focusing on treatment of metastatic breast cancer was held on May 16, 2020
  • The group of advisors comprised 13 community oncologists from the southwest region of the US
  • Data collection was accomplished through use of audience response system questioning and moderated discussion

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.